Clinical significance of heterozygosity loss at Mfn2 gene in hepatocellular carcinoma.

Author: Li QU ¹ ; Wei-Ling WANG ; Jian-Feng WEI ; Wu-Hua ZHOU ; Shu-Sen ZHENG
Author Information

1. Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Publication Type:Journal Article
MeSH: Adult; Aged; Carcinoma, Hepatocellular; genetics; Female; GTP Phosphohydrolases; Humans; Liver Neoplasms; genetics; Loss of Heterozygosity; Male; Membrane Proteins; genetics; Middle Aged; Mitochondrial Proteins; genetics
From: Journal of Zhejiang University. Medical sciences 2010;39(5):506-510
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo investigate the loss of heterozygosity (LOH) at mitofusin-2 (Mfn2) gene in hepatocellular carcinoma (HCC) and its clinicopathological significance.
METHODSFour high polymorphic microsatellite markers flanking Mfn2 were selected for LOH analysis in 29 cases of HCC.
RESULTThe frequencies of LOH on D1S2667, D1S2740, D1S434 and D1S228 were 21%, 23%, 21% and 22%, respectively. LOH at Mfn2 was closely correlated with tumor size, age, capsule, differentiation and t HBV infection (P<0.05), not with gender, thrombosis, cirrhosis and serum AFP levels (P>0.05).
CONCLUSIONLOH at Mfn2 gene in HCC is associated with the clinicopathological features of patients.